Tumor-derived lactic acid promotes the expression of the autophagy enhancing protein RUBCNL through histone H3 lysine-18 lactation (H3K18la), thereby promoting the resistance of colorectal cancer to bevacizumab therapy. This evidence concerns the gene RUBCNL and neoplasm.